Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Up 2.86% on Mar 31
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Up 2.86% on Mar 31
Fiscal Year: January - December
Teva Pharmaceutical Industries Limited (TEVA), listed on the NYSE, has a market capitalization of $35.03B. As of Apr 06, 2026, the stock is trading at $30.08 per share@else an unavailable price , offering investors a clear view of its current market value. Teva Pharmaceutical Industries Limited is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 24.86, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Teva Pharmaceutical Industries Limited also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Teva Pharmaceutical Industries Limited (TEVA) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Teva Pharmaceutical Industries Limited is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Teva Pharmaceutical Industries Limited, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Teva Pharmaceutical Industries Limited is 30.51, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Teva Pharmaceutical Industries Limited (TEVA) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Teva Pharmaceutical Industries Limited (TEVA) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Teva Pharmaceutical Industries Limited (TEVA) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Teva Pharmaceutical Industries Limited. To access the full SS Score, consider upgrading your subscription.
Teva Pharmaceutical Industries Limited is a significant player in the industry sector, with a market capitalization of $35.03B and a competitive P/E ratio of 24.86. Investors should compare these metrics with industry peers to gauge whether Teva Pharmaceutical Industries Limited is outperforming or underperforming within its sector.
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Up 2.86% on Mar 31
Teva (TEVA) Advances with Biosimilar Application Review for Xolair
FDA Approves Teva's (TEVA) Ponlimsi as Prolia Biosimilar
Teva Pharmaceutical Industries Ltd (TEVA) Shares Down 3.49% on Mar 30
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab Fundamental International Large Company Index (Symbol: FNDF) wh...
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), Monday announced that the U.S. Food and Drug Administration has approved PONLIMSI as a biosimilar to Prolia, to treat a variety of debilitati...
TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demons...
Insider Sell: Mark Sabag Sells 62,102 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its...
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quar...
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Brookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years. SSR Mining remains one of the best ways to capitalize on rising pr...
TEVA, Sandoz and Dr. Reddy's are shifting toward complex generics and biosimilars to counter pricing pressure and strengthen margins in the competitive generics market.
Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.
Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.
Piper Sandler Updates Analyst Rating on TEVA, Raises Price Target | TEVA Stock News
Form 13Fs help investors track which stocks and exchange-traded funds (ETFs) Wall Street's most successful money managers bought and sold in the latest quarter. Profit-taking looks to have been on bil...
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA) and funds managed by Blackstone Life Sciences announced a $400 million strategic funding agreement spread ac...
Teva Pharmaceutical (TEVA) Secures $400M Funding for Duvakitug Development
Blackstone (BX) Commits $400M to Teva for Duvakitug Development
Teva Pharmaceutical Industries Ltd (TEVA) Shares Gap Down to $32.22 on Mar 3
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the com...
Eliyahu Kalif Sells 345,810 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 1.62B | 116.69% | Est @116.7% |
| 2026 | 2.50B | 53.85% | Analyst x4 |
| 2027 | 3.22B | 28.86% | Analyst x3 |
| 2028 | 3.82B | 18.65% | Analyst x3 |
| 2029 | 4.03B | 5.55% | Analyst x2 |
| 2030 | 4.12B | 2.28% | Analyst x2 |
| 2031 | 4.20B | 1.85% | Est @1.9% |
| 2032 | 4.28B | 2.07% | Est @2.1% |
| 2033 | 4.38B | 2.21% | Est @2.2% |
| 2034 | 4.47B | 2.16% | Est @2.2% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 842.00M | 1.00 | 842.00M |
| 2024A | 749.00M | 1.00 | 749.00M |
| 2025E | 1.62B | 1.08 | 1.50B |
| 2026E | 2.50B | 1.17 | 2.14B |
| 2027E | 3.22B | 1.26 | 2.55B |
| 2028E | 3.82B | 1.36 | 2.81B |
| 2029E | 4.03B | 1.47 | 2.74B |
| 2030E | 4.12B | 1.59 | 2.60B |
| 2031E | 4.20B | 1.71 | 2.45B |
| 2032E | 4.28B | 1.85 | 2.32B |
| 2033E | 4.38B | 2.00 | 2.19B |
| 2034E | 4.47B | 2.16 | 2.07B |
| Terminal | 83.40B | 2.16 | 38.64B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.